♜ Fallacy 5: EU HTA affects only Market Access and HEOR – really?♜

 

🌍 Usually, EU HTA tasks are handled by Market Access and HOER. Market Access understands the local reimbursement requirements best, HEOR is more familiar with the actual evidence, including the evidence generation plan.

 

But can we assign the resonsibility to one of these two functions and continue business as usual❓

 

❌ The answer is NO!

It is definitely a cross-functional approach, involving following points:

➡️ JSC affects clinical development in informing study design,

➡️ Regulatory on label strategies, and thereby on commercial positioning,

➡️ JCA requires input from Regulatory regarding timelines,

➡️ Affiliates on local access strategies,

➡️ Statistics for data presentation.